Kinase Domain Mutation detection indicates risk of disease progression

Researchers from Imperial College London have published data showing that screening of patients for bcr-abl mutations following imatinib treatment can indicate a patient’s risk of disease progression

YM Biosciences EGFR MAb nimotuzumab safe in Phase I

Data to be presented at the AACR Centennial Conference on Translational Cancer Medicine today will detail YM Biosciences EGFR MAb nimotuzumab’s favorable side-effect profile. Data from an ongoing phase II study in colorectal cancer  has confirmed a low level of interaction between nimotuzumab and normal tissue with less than a quarter of the patients exhibiting [...]